Deborah M Young

US Patent:

7618632, Nov 17, 2009

Filed:

May 24, 2004

Appl. No.:

10/853032

Inventors:

Mary Collins - Natick MA, US
Ethan Menahem Shevach - Rockville MD, US
Rebecca Suzanne McHugh - Wellington, NZ
Matthew James Whitters - Hudson MA, US
Deborah Ann Young - Melrose MA, US
Michael Chapman Byrne - Brookline MA, US
Padmalatha S. Reddy - Walpole MA, US
Geoffrey Laurence Stephens - Damascus MD, US
Beatriz M. Carreno - Acton MA, US

Assignee:

Wyeth - Madison NJ
The United States of America as represented by the Secretary of the Department of Health and Human Services - Washington DC

International Classification:

A61K 39/395
C07K 16/00

US Classification:

4241441, 53038822

Abstract:

The present invention provides novel isolated and purified polynucleotides and polypeptides related to a novel ligand for glucocorticoid-induced TNF receptor (GITR). The invention also provides antibodies to the GITR ligand (GITRL). The present invention also is directed to novel methods for diagnosing, prognosing, monitoring the progress of, and treating disorders arising from disregulation of the immune system (e. g. , autoimmune disorders, inflammatory diseases, and transplant rejection, and cancers and infectious diseases) using GITRL and/or modulators of GITRL. The present invention is further directed to novel therapeutics and therapeutic targets and to methods of screening and assessing test compounds for the intervention (treatment) and prevention of said disorders arising from disregulation of the immune system, as related to GITRL and GITR.

US Patent:

20060159655, Jul 20, 2006

Filed:

Mar 22, 2004

Appl. No.:

10/806611

Inventors:

Mary Collins - Natick MA, US
Elaine Chin - Concord MA, US
Mayra Senices - Peabody MA, US
Deborah Young - Melrose MA, US

Assignee:

Wyeth - Madison NJ

International Classification:

A61K 38/21
A61K 39/395
A61K 31/525
A61K 31/4745
A61K 38/20

US Classification:

424085200, 424143100, 424085500, 424085600, 424085700, 514291000, 514251000

Abstract:

Methods and compositions for modulating interleukin-21 (IL-21)/IL-21 receptor (MU-1) activity using agonists of IL-21 or IL-21 receptor (“IL-21R” or “MU-1”), are disclosed. IL-21/IL-21R agonists can be used by themselves or in combination with anti-inflammatory agents to treat, e.g., ameliorate, symptoms associated with immunological disorders of the nervous system, e.g., multiple sclerosis.

US Patent:

20100080809, Apr 1, 2010

Filed:

Aug 28, 2009

Appl. No.:

12/550244

Inventors:

Mary Collins - Natick MA, US
Ethan Menahem Shevach - Rockville MD, US
Rebecca Suzanne McHugh - Wellington, NZ
Matthew James Whitters - Hudson MA, US
Deborah Ann Young - Melrose MA, US
Michael Chapman Byrne - Brookline MA, US
Padmalatha S. Reddy - Walpole MA, US
Geoffrey Laurence Stephens - Damascus MD, US
Beatriz M. Carreno - Acton MA, US

Assignee:

Wyeth - Madison NJ
The Government of the United States - Rockville MD

International Classification:

A61K 39/395
C07H 21/04
A01K 67/00
C07K 14/435
C07H 21/02
G01N 33/53
C12Q 1/68
C12N 5/02
A61K 35/12

US Classification:

4241441, 536 235, 800 13, 530350, 536 245, 435 71, 435 6, 435375, 424 9371

Abstract:

The present invention provides novel isolated and purified polynucleotides and polypeptides related to a novel ligand for glucocorticoid-induced TNF receptor (GITR). The invention also provides antibodies to the GITR ligand (GITRL). The present invention also is directed to novel methods for diagnosing, prognosing, monitoring the progress of, and treating disorders arising from disregulation of the immune system (e.g., autoimmune disorders, inflammatory diseases, and transplant rejection, and cancers and infectious diseases) using GITRL and/or modulators of GITRL. The present invention is further directed to novel therapeutics and therapeutic targets and to methods of screening and assessing test compounds for the intervention (treatment) and prevention of said disorders arising from disregulation of the immune system, as related to GITRL and GITR.